Interestingly, unlike Exendin-4 and Linagliptin that affect both hyperglycemia and insulin resistance, Empagliflozin specifically attenuated hyperglycemia without affecting insulin sensitivity, indicating that sustained glycemic control post-stroke might be sufficient to improve stroke recovery in diabetes. The gene discussed is INS; the disease is Insulin resistance.